2021年度

Kojima T, Yuno A, Hirayama M, Fukuma D, Shinohara M, Nishimura Y, Nakayama H.
Development of HLA-modified induced pluripotent stem cell-derived dendritic cells applicable for a novel cancer immunotherapy.
Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology. 2022;34(5): 643-652

Naito H, Sueta D, Hanatani S, Ikeda H, Hirosue A, Senokuchi T, Araki E, Tsujita K, Nakayama H, Kasaoka S.
Factors Affecting Human Damage in Heavy Rains and Typhoon Disasters.
Tohoku J Exp Med. 2022;256(2):175-185.

Suzuki-Karasaki M, Ando T, Ochiai Y, Kawahara K, Suzuki-Karasaki M, Nakayama H, Suzuki-Karasaki Y.
Air Plasma-Activated Medium Evokes a Death-Associated Perinuclear Mitochondrial Clustering.
Int J Mol Sci. 2022;23(3):1124.

Liu R, Shinriki S, Maeshiro M, Hirayama M, Jono H, Yoshida R, Nakayama H, Matsui H.
The Tumour Suppressor CYLD Is Required for Clathrin-Mediated Endocytosis of EGFR and Cetuximab-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma.
Cancers (Basel). 2021;14(1):173.

Yamana K, Inoue J, Yoshida R, Sakata J, Nakashima H, Arita H, Kawaguchi S, Gohara S, Nagao Y, Takeshita H, Maeshiro M, Liu R, Matsuoka Y, Hirayama M, Kawahara K, Nagata M, Hirosue A, Toya R, Murakami R, Kuwahara Y, Fukumoto M, Nakayama H.
Extracellular vesicles derived from radioresistant oral squamous cell carcinoma cells contribute to the acquisition of radioresistance via the miR-503-3p-BAK axis.
J Extracell Vesicles. 2021;10(14):e12169.

Masuda N, Tamura K, Yasojima H, Shimomura A, Sawaki M, Lee MJ, Yuno A, Trepel J, Kimura R, Nishimura Y, Saji S, Iwata H.
Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer.
BMC Cancer. 2021;21(1):1269.

Kawahara K, Nagata M, Yoshida R, Hirosue A, Tanaka T, Matsuoka Y, Arita H, Nakashima H, Sakata J, Yamana K, Kawaguchi S, Gohara S, Nagao Y, Hirayama M, Takahashi N, Hirayama M, Nakayama H.
miR-30a attenuates drug sensitivity to 5-FU by modulating cell proliferation possibly by downregulating cyclin E2 in oral squamous cell carcinoma.
Biochem Biophys Rep. 2021;28:101114.

Carraway HE, Sawalha Y, Gojo I, Lee MJ, Lee S, Tomita Y, Yuno A, Greer J, Smith BD, Pratz KW, Levis MJ, Gore SD, Ghosh N, Dezern A, Blackford AL, Baer MR, Gore L, Piekarz R, Trepel JB, Karp JE.
Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia.
Leuk Res. 2021;110:106707.

Gohara S, Yoshida R, Kawahara K, Sakata J, Arita H, Nakashima H, Kawaguchi S, Nagao Y, Yamana K, Nagata M, Hirosue A, Hiraki A, Nakayama H.
Re-evaluating the clinical significance of serum p53 antibody levels in patients with oral cancer in Japanese clinical practice.
Mol Clin Oncol. 2021;15(4):209.

Minamitake A, Murakami R, Sakamoto F, Yoshida R, Sakata J, Hirosue A, Kawahara K, Yamana K, Nakayama H, Toya R, Shiraishi S.
Can MRI-derived depth of invasion predict nodal recurrence in oral tongue cancer?
Oral Radiol. 2021;37(4):641-646

Kawahara K, Hiraki A, Arita H, Takeshita H, Hirosue A, Matsuoka Y, Sakata J, Obayashi Y, Nakashima H, Hirayama M, Nagata M, Yoshida R, Shinohara M, Nakayama H.
Role of serum amylase and salivary cytokines in oral complications during chemoradiotherapy.
2021;27(6):1564-1571.

Zhang M, Hong JA, Kunst TF, Bond CD, Kenney CM, Warga CL, Yeray J, Lee MJ, Yuno A, Lee S, Miettinen M, Ripley RT, Hoang CD, Gnjatic S, Trepel JB, Schrump DS.
Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies.
Transl Lung Cancer Res. 2021;10(7):3079-3092.

Thomas A, Takahashi N, Rajapakse VN, Zhang X, Sun Y, Ceribelli M, Wilson KM, Zhang Y, Beck E, Sciuto L, Nichols S, Elenbaas B, Puc J, Dahmen H, Zimmermann A, Varonin J, Schultz CW, Kim S, Shimellis H, Desai P, Klumpp-Thomas C, Chen L, Travers J, McKnight C, Michael S, Itkin Z, Lee S, Yuno A, Lee MJ, Redon CE, Kindrick JD, Peer CJ, Wei JS, Aladjem MI, Figg WD, Steinberg SM, Trepel JB, Zenke FT, Pommier Y, Khan J, Thomas CJ.
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.
Cancer Cell. 2021;39(4):566-579.e7.

Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer.
Madan RA, Karzai FH, Al Harthy M, Petrylak DP, Kim JW, Arlen PM, Rosner I, Theoret MR, Cordes L, Bilusic M, Peer CJ, Dawson NA, Couvillon A, Hankin A, Williams M, Chun G, Owens H, Marte JL, Lee MJ, Tomita Y, Yuno A, Trepel JB, Lee S, Steinberg SM, Gulley JL, Figg WD, Dahut WL.
BJU Int. 2021;127(4):435-444.